The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and ...

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

Plaque psoriasis-often mistaken for dry skin or eczema-isn't always easy to manage and usually causes discomfort. Recently, the actress and TV personality opened up to First For Women about her ...

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE ...

Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than ...

The trial investigators wanted to see if the drug was an effective psoriasis treatment because of its immune-dampening and itch-reducing effects. A total of 432 patients (56.3% women) aged 12 and ...

An analysis of a large general practice database showed that patients with severe plaque psoriasis for 3-6 years had a 50% higher relative risk of premature mortality. On average, men and women ...

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD Topline ...

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB’s Bimzelx achieved complete skin clearance. After five years of continued ...